The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 08, 2019

Filed:

Jan. 20, 2016
Applicant:

D.r.nano Co., Ltd, Seoul, KR;

Inventors:

Sehoon Kim, Seoul, KR;

Ick Chan Kwon, Seoul, KR;

Eunjung Lee, Seoul, KR;

Assignee:

D.R.NANO CO., LTD, Seoul, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/54 (2017.01); A61K 31/713 (2006.01); A61K 31/14 (2006.01); C12N 15/113 (2010.01); A61K 9/107 (2006.01); A61K 47/34 (2017.01); A61K 47/10 (2017.01); C12N 15/11 (2006.01);
U.S. Cl.
CPC ...
A61K 31/713 (2013.01); A61K 9/1075 (2013.01); A61K 31/14 (2013.01); A61K 47/10 (2013.01); A61K 47/34 (2013.01); A61K 47/541 (2017.08); C12N 15/111 (2013.01); C12N 15/1135 (2013.01); C12N 2310/11 (2013.01); C12N 2310/12 (2013.01); C12N 2310/14 (2013.01); C12N 2310/16 (2013.01); C12N 2310/531 (2013.01); C12N 2320/30 (2013.01); C12N 2320/31 (2013.01); C12N 2320/32 (2013.01);
Abstract

The present invention relates to a nanocomplex, and a pharmaceutical composition, a drug delivery system and a drug delivery method using the same. The present nanocomplex consists of a nucleic acid molecule, a monocationic drug and a biocompatible polymer surfactant, and not only has a hydrodynamic size of 10 nm or less, but uniformly distributes as a colloidal form in an aqueous environment. In addition, the nanoscale colloidal formulation of the present invention could protect the nucleic acid molecule from a nuclease (for example, serum nucleases) rich in a physiological environment through the formulation of a stable monocomplex, and provide improvement of cell penetration and in vivo delivery via a micellar structure as well as further protection of the nucleic acid molecule by a micellar passivation. Therefore, the present nanocomplex and a composition and system using the same can deliver an active ingredient (for example, a nucleic acid molecule and monocationic drug) into a cell/tissue of interest in a stable manner, and may be effectively applied for treating or detecting diverse disorders (practically, cancers).


Find Patent Forward Citations

Loading…